Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2/3 1

Status

Recruiting 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Thoracic 1

Conditions

Meningeal Neoplasms 1Inhibition, Psychological 1Hereditary Sensory and Autonomic Neuropathies 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 118Specimen Handling 104pembrolizumab 103Magnetic Resonance Spectroscopy 95fludarabine 93Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 37Paclitaxel 35Cetuximab 35Carboplatin 35Radiotherapy 31Oxaliplatin 30fludarabine phosphate 29Gemcitabine 29Leucovorin 28Drug Therapy 25Ipilimumab 23Immunotherapy, Adoptive 23Azacitidine 23Radiation 21Irinotecan 21Temozolomide 20130-nm albumin-bound paclitaxel 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × AZD1390 × Clear all
NCT06894979 2026-05-15

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Children's Oncology Group

Phase 1 Recruiting
54 enrolled
CNS

Astrocytoma

NCT03423628 2025-12-22

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

AstraZeneca

Phase 1 Recruiting
180 enrolled
CNS

Brain Neoplasms, Glioblastoma, Inhibition, Psychological, Meningeal Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT04550104 2025-12-19

CONCORDE

University of Leeds

Phase 1 Recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡